Xtant Medical stock reports a second quarter revenue miss

Xtant Medical stock reported second quarter revenue of USD 23.03 million for the period ended June 30, 2026, below the USD 24.88 million analyst estimate. The result puts the medical device maker's profitability and revenue trajectory at the center of the investment case.

Revenue misses estimates

According to MarketBeat on September 25, 2026, Xtant reported a quarterly GAAP loss of USD 0.07 per share against a consensus loss of USD 0.02. Revenue of USD 23.03 million also missed the USD 24.88 million estimate by USD 1.85 million, or 7.43 percent.

The figures relate to the second quarter released on August 11, 2026. Xtant's latest quarterly revenue therefore came with a larger loss than analysts expected, giving the earnings miss more weight than the revenue gap alone.

Analyst target stays higher

Investing.com reported on September 2, 2026, that Lucid Capital Markets initiated coverage with a Buy rating and a USD 1.00 price target. The research firm highlighted Xtant's ability to manufacture five orthobiologics product categories in-house and its potential OEM and private-label role.

Xtant describes itself as a medical technology company focused on regenerative biologics and spinal implant systems, serving orthopedic and neurological surgeons. Its investor-relations page identifies the common stock as NYSE MKT listed under XTNT, now known as NYSE American.

Small-cap valuation remains wide

As of September 29, 2026, Xtant had a market capitalization of USD 50.6 million. The stock's 52-week range was USD 0.27 to USD 0.95, while the latest primary-exchange quote stood at USD 0.36 at 3:45 p.m. ET.

The valuation gap between that quote and Lucid Capital's USD 1.00 target is substantial, but the second-quarter loss and revenue miss are equally concrete counterweights. For investors, the next assessment depends on whether revenue can recover from the USD 23.03 million quarterly base while losses narrow.